AstraZeneca Signs Deal to Tackle Japan's Drug Lag (Japan)
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical giant AstraZeneca announced Sept. 26 it had entered a partnership with Tokyo's prestigious Keio University School of Medicine. Currently, there is a significant delay between the time drugs debut in Europe and North American and when they are made available to Japanese patients. By partnering with Keio, AstraZeneca hopes to solve this problem by increasing the number of early clinical trials conducted in Japan. (Click here for more